Non Animal Testing, Alternative Test Methods, In Vitro Toxicology, IIVS | Documents & Resources
573
paged,page-template-default,page,page-id-573,page-child,parent-pageid-163,paged-5,page-paged-5,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-17.2,qode-theme-bridge,disabled_footer_bottom,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive

Documents & Resources

In Vitro Assessment of Skin Irritation Potential of Surfactant-based Formulations by Using a 3-D Skin Reconstructed Tissue Model and Cytokine Response

January 24, 2017

The personal care industry is focused on developing safe, more efficacious, and increasingly milder products, that are routinely undergoing preclinical and clinical testing before becoming available for consumer use on skin. In vitro systems based on skin reconstructed equivalents are now established for the preclinical assessment of product irritation potential and as alternative testing methods to the classic Draize rabbit skin irritation test. We have used the 3-D EpiDerm™ model system to evaluate tissue viability and primary cytokine interleukin-1α release as a way to evaluate the potential dermal irritation of 224 non-ionic, amphoteric and/or anionic surfactant-containing formulations, or individual raw materials. Full article available to full and paid subscribers of ATLA.

The Use of Human 3D Reconstructed Airway Cultures for Tobacco Product Evaluation: Precision Low-Volume Exposures at the Apical Site

January 10, 2017

With a mandate to evaluate the dynamics of pulmonary exposure to inhaled materials such as tobacco-based products, researchers are employing complex, human, three-dimensional pulmonary models. Human reconstructed airway (RHuA) tissues present a platform that more closely resembles airways in vivo. Grown at the air–liquid interface (ALI), RHuA tissues offer apical and basal compartments that allow flexibility in modeling physiologically relevant exposures and provide sampling location-specific results. Read the full article.

Trends in Regenerative Medicine: Repigmentation in Vitiligo Through Melanocyte Stem Cell Mobilization

December 28, 2016

Vitiligo is the most frequent human pigmentary disorder, characterized by progressive autoimmune destruction of mature epidermal melanocytes. Of the current treatments offering partial and temporary relief, ultraviolet (UV) light is the most effective, coordinating an intricate network of keratinocyte and melanocyte factors that control numerous cellular and molecular signaling pathways. Read the full article.

Decoding and Modulating the Color of Human Skin

November 22, 2016

The constitutive color of human skin varies widely across the globe, from the very pale as in Celtic skin to the very dark present in regions such as sub-Saharan Africa. There is a biologic player “hard at work” producing the pigments that generate great variations in human skin color and is the protagonist of this article. It is the melanocyte. Read the full article.  

Video: The 3T3 Neutral Red Uptake Phototoxicity Test — Chinese

November 21, 2016

This training video with Chinese subtitles explores a cell-based method for assessing Phototoxicity — or the potential for chemicals to cause damage after being exposed to light. The method is used widely around the world by many industries, including the cosmetics and pharmaceutical sectors. Disclaimer: Please note that the procedures shown in this video were ...

Video: The 3T3 Neutral Red Uptake Phototoxicity Test — Portuguese

November 21, 2016

This new training video with Portuguese subtitles explores a cell-based method for assessing Phototoxicity — or the potential for chemicals to cause damage after being exposed to light. The method is used widely around the world by many industries, including the cosmetics and pharmaceutical sectors. Disclaimer: Please note that the procedures shown in this video were for ...

Webinar: How GLPs Enhance the Quality of Regulated and Non-Regulated Toxicology

October 18, 2016

This one-hour webinar, led by IIVS Director of Quality and Compliance, introduces some of the concepts of Good Laboratory Practices (GLPs) designed to promote study and data integrity within an in vitro toxicology framework. Applying these concepts within your own laboratory should aid in production of robust, repeatable studies. 3T3 Neutral Red Uptake | Acute Respiratory Toxicity | Assessing Corneal Recovery | BCOP | Bronchial/Tracheal | CAMVA | Chronic Respiratory Toxicity | Ciliary Beat Frequency | Corneal Recovery Modeling | Corrositex

International Harmonization and Cooperation in the Validation of Alternative Methods

September 27, 2016

The development and validation of scientific alternatives to animal testing is important not only from an ethical perspective (implementation of 3Rs), but also to improve safety assessment decision making with the use of mechanistic information of higher relevance to humans. To be effective in these efforts, it is however imperative that validation centres, industry, regulatory bodies, academia and other interested parties ensure a strong international cooperation, cross-sector collaboration and intense communication in the design, execution, and peer review of validation studies. Read chapter.

Implementation of New Test Methods into Practical Testing

September 27, 2016

New toxicology test methods, especially those using in vitro methods, are continually being developed. Some are used by industry for screening purposes; others are eventually validated for regulatory use. However, for a new test method to be firmly adopted by industry it must be readily available, generally through an in-house industry laboratory, an academic laboratory, or a contract research organization. Read chapter.  

Webinar: Regulatory Initiatives for New Approaches to Traditional Toxicity Testing

July 1, 2016

This one-hour webinar features presentations by Dr. Jennifer McLain, Deputy Director, Office of Pesticide Programs, Antimicrobial Division and IIVS CEO Dr. Rodger Curren. Dr. McLain discusses the EPA OPP's plans to reduce the use of animal testing in acute toxicity testing and provides suggestions on how stakeholders and EPA can cooperate to advance animal reduction goals. Dr. Curren then talks ...